spacer
spacer

PDBsum entry 1ivo

Go to PDB code: 
protein ligands Protein-protein interface(s) links
Transferase/signaling protein PDB id
1ivo
Jmol
Contents
Protein chains
511 a.a. *
47 a.a. *
Ligands
NAG ×8
NAG-NAG
Waters ×79
* Residue conservation analysis
PDB id:
1ivo
Name: Transferase/signaling protein
Title: Crystal structure of the complex of human epidermal growth f receptor extracellular domains.
Structure: Epidermal growth factor receptor. Chain: a, b. Fragment: extracellular domains i, ii, ii and iv. Engineered: yes. Epidermal growth factor. Chain: c, d. Fragment: residues 1-53. Synonym: egf. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Expressed in: cricetulus griseus. Expression_system_taxid: 10029. Expressed in: escherichia coli. Expression_system_taxid: 562
Biol. unit: Dimer (from PQS)
Resolution:
3.30Å     R-factor:   0.255     R-free:   0.326
Authors: H.Ogiso,R.Ishitani,O.Nureki,S.Fukai,M.Yamanaka,J.H.Kim,K.Sai M.Shirouzu,S.Yokoyama,Riken Structural Genomics/proteomics Initiative (Rsgi)
Key ref:
H.Ogiso et al. (2002). Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell, 110, 775-787. PubMed id: 12297050 DOI: 10.1016/S0092-8674(02)00963-7
Date:
28-Mar-02     Release date:   16-Oct-02    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
Pfam   ArchSchema ?
P00533  (EGFR_HUMAN) -  Epidermal growth factor receptor
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1210 a.a.
511 a.a.
Protein chains
Pfam   ArchSchema ?
P01133  (EGF_HUMAN) -  Pro-epidermal growth factor
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1207 a.a.
47 a.a.
Key:    PfamA domain  PfamB domain  Secondary structure  CATH domain

 Enzyme reactions 
   Enzyme class: Chains A, B: E.C.2.7.10.1  - Receptor protein-tyrosine kinase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate
ATP
+
[protein]-L-tyrosine
Bound ligand (Het Group name = NAG)
matches with 47.62% similarity
= ADP
+ [protein]-L-tyrosine phosphate
Molecule diagrams generated from .mol files obtained from the KEGG ftp site
 Gene Ontology (GO) functional annotation 
  GO annot!
  Cellular component     membrane   1 term 
  Biological process     transmembrane receptor protein tyrosine kinase signaling pathway   2 terms 
  Biochemical function     ATP binding     2 terms  

 

 
    reference    
 
 
DOI no: 10.1016/S0092-8674(02)00963-7 Cell 110:775-787 (2002)
PubMed id: 12297050  
 
 
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains.
H.Ogiso, R.Ishitani, O.Nureki, S.Fukai, M.Yamanaka, J.H.Kim, K.Saito, A.Sakamoto, M.Inoue, M.Shirouzu, S.Yokoyama.
 
  ABSTRACT  
 
Epidermal growth factor (EGF) regulates cell proliferation and differentiation by binding to the EGF receptor (EGFR) extracellular region, comprising domains I-IV, with the resultant dimerization of the receptor tyrosine kinase. In this study, the crystal structure of a 2:2 complex of human EGF and the EGFR extracellular region has been determined at 3.3 A resolution. EGFR domains I-III are arranged in a C shape, and EGF is docked between domains I and III. The 1:1 EGF*EGFR complex dimerizes through a direct receptor*receptor interaction, in which a protruding beta-hairpin arm of each domain II holds the body of the other. The unique "receptor-mediated dimerization" was verified by EGFR mutagenesis.
 
  Selected figure(s)  
 
Figure 3.
Figure 3. Interactions between EGF and EGFREGF and the EGFR domains are colored in the same manner as in Figure 1, except for (B).(A) Mapping the interaction sites onto ribbon representations of EGFR and EGF. Three binding sites in the interface are outlined.(B) EGF structure. The A, B, and C loops are colored blue, green, and red, respectively. The other regions are pale green.(C) Stereo view of the interface at site 1. Only the side chains of interacting residues are shown. Dotted lines represent hydrogen bonds.(D) Stereo view of the interface at site 2.(E) Stereo view of the interface at site 3.
Figure 4.
Figure 4. Interactions between Each Receptor in the Dimer Interface(A) The binding region in the interface is outlined. Only the side chains of interacting residues are shown. EGF and the EGFR domains are colored in the same manner as in Figure 1.(B) Stereo view of an annealed omit map. Residues 240–260 and the residues within 3.5 Å from them of one EGRF molecule (orange) were omitted.(C) Stereo view of the interface from the view shown by the arrow in (A); the view is directed from the front side of domain I toward Y251 of the other receptor. Dotted lines represent hydrogen bonds.(D) Stereo view of the interface from the view shown by the arrow in (A); the view is directed from the back side of domain I toward Y251 of the other receptor.
 
  The above figures are reprinted by permission from Cell Press: Cell (2002, 110, 775-787) copyright 2002.  
  Figures were selected by an automated process.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
22785351 Y.Yarden, and G.Pines (2012).
The ERBB network: at last, cancer therapy meets systems biology.
  Nat Rev Cancer, 12, 553-563.  
21822280 L.Z.Mi, C.Lu, Z.Li, N.Nishida, T.Walz, and T.A.Springer (2011).
Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor.
  Nat Struct Mol Biol, 18, 984-989.  
21287620 N.Chennamsetty, V.Voynov, V.Kayser, B.Helk, and B.L.Trout (2011).
Prediction of protein binding regions.
  Proteins, 79, 888-897.  
21364581 Q.Sheng, and J.Liu (2011).
The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.
  Br J Cancer, 104, 1241-1245.  
20673774 R.E.Hubbard (2011).
Structure-based drug discovery and protein targets in the CNS.
  Neuropharmacology, 60, 7.  
22101934 Z.Wang, P.A.Longo, M.K.Tarrant, K.Kim, S.Head, D.J.Leahy, and P.A.Cole (2011).
Mechanistic insights into the activation of oncogenic forms of EGF receptor.
  Nat Struct Mol Biol, 18, 1388-1393.  
20589763 A.B.Pfister, R.C.Wood, P.J.Salas, D.L.Zea, and V.P.Ramsauer (2010).
Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling.
  J Cell Biochem, 111, 643-652.  
20514015 C.Hartmann, N.Müller, A.Blaukat, J.Koch, I.Benhar, and W.S.Wels (2010).
Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response.
  Oncogene, 29, 4517-4527.  
20723758 D.Alvarado, D.E.Klein, and M.A.Lemmon (2010).
Structural basis for negative cooperativity in growth factor binding to an EGF receptor.
  Cell, 142, 568-579.
PDB codes: 3ltf 3ltg
20459566 F.F.Barros, D.G.Powe, I.O.Ellis, and A.R.Green (2010).
Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments.
  Histopathology, 56, 560-572.  
20304480 G.Mehta, C.M.Williams, L.Alvarez, M.Lesniewski, R.D.Kamm, and L.G.Griffith (2010).
Synergistic effects of tethered growth factors and adhesion ligands on DNA synthesis and function of primary hepatocytes cultured on soft synthetic hydrogels.
  Biomaterials, 31, 4657-4671.  
20105326 J.A.Laisney, I.Braasch, R.B.Walter, S.Meierjohann, and M.Schartl (2010).
Lineage-specific co-evolution of the Egf receptor/ligand signaling system.
  BMC Evol Biol, 10, 27.  
20616078 J.B.Spangler, J.R.Neil, S.Abramovitch, Y.Yarden, F.M.White, D.A.Lauffenburger, and K.D.Wittrup (2010).
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling.
  Proc Natl Acad Sci U S A, 107, 13252-13257.  
20432069 J.H.Bae, and J.Schlessinger (2010).
Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases.
  Mol Cells, 29, 443-448.  
20208353 K.Nagata (2010).
Studies of the structure-activity relationships of peptides and proteins involved in growth and development based on their three-dimensional structures.
  Biosci Biotechnol Biochem, 74, 462-470.  
21119106 L.Chen, J.Placone, L.Novicky, and K.Hristova (2010).
The extracellular domain of fibroblast growth factor receptor 3 inhibits ligand-independent dimerization.
  Sci Signal, 3, ra86.  
20190183 M.Cardó-Vila, R.J.Giordano, R.L.Sidman, L.F.Bronk, Z.Fan, J.Mendelsohn, W.Arap, and R.Pasqualini (2010).
From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway.
  Proc Natl Acad Sci U S A, 107, 5118-5123.  
20087512 M.Kitamatsu, M.Futami, and M.Sisido (2010).
A novel method for screening peptides that bind to proteins by using multiple fluorescent amino acids as fluorescent tags.
  Chem Commun (Camb), 46, 761-763.  
20813958 P.Nagy, J.Claus, T.M.Jovin, and D.J.Arndt-Jovin (2010).
Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis.
  Proc Natl Acad Sci U S A, 107, 16524-16529.  
20933094 P.Sanchez-Soria, and T.D.Camenisch (2010).
ErbB signaling in cardiac development and disease.
  Semin Cell Dev Biol, 21, 929-935.  
20635913 B.Markman, J.Capdevila, E.Elez, and J.Tabernero (2009).
New trends in epidermal growth factor receptor-directed monoclonal antibodies.
  Immunotherapy, 1, 965-982.  
19518076 C.Qiu, M.K.Tarrant, T.Boronina, P.A.Longo, J.M.Kavran, R.N.Cole, P.A.Cole, and D.J.Leahy (2009).
In vitro enzymatic characterization of near full length EGFR in activated and inhibited states.
  Biochemistry, 48, 6624-6632.  
19718021 D.Alvarado, D.E.Klein, and M.A.Lemmon (2009).
ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor.
  Nature, 461, 287-291.
PDB code: 3i2t
19165838 D.S.Miller, S.Chirayil, H.L.Ball, and K.J.Luebke (2009).
Manipulating cell migration and proliferation with a light-activated polypeptide.
  Chembiochem, 10, 577-584.  
19818651 J.Back, E.L.Malchiodi, S.Cho, L.Scarpellino, P.Schneider, M.C.Kerzic, R.A.Mariuzza, and W.Held (2009).
Distinct conformations of Ly49 natural killer cell receptors mediate MHC class I recognition in trans and cis.
  Immunity, 31, 598-608.
PDB codes: 3g8k 3g8l
19536107 J.Baselga, and S.M.Swain (2009).
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.
  Nat Rev Cancer, 9, 463-475.  
19269105 J.Capdevila, E.Elez, T.Macarulla, F.J.Ramos, M.Ruiz-Echarri, and J.Tabernero (2009).
Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment.
  Cancer Treat Rev, 35, 354-363.  
19390622 J.F.Flynn, C.Wong, and J.M.Wu (2009).
Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer.
  J Oncol, 2009, 526963.  
19740107 J.Klingelhöfer, H.D.Møller, E.U.Sumer, C.H.Berg, M.Poulsen, D.Kiryushko, V.Soroka, N.Ambartsumian, M.Grigorian, and E.M.Lukanidin (2009).
Epidermal growth factor receptor ligands as new extracellular targets for the metastasis-promoting S100A4 protein.
  FEBS J, 276, 5936-5948.  
19336395 J.L.Macdonald-Obermann, and L.J.Pike (2009).
The intracellular juxtamembrane domain of the epidermal growth factor (EGF) receptor is responsible for the allosteric regulation of EGF binding.
  J Biol Chem, 284, 13570-13576.  
19196031 J.L.Macdonald-Obermann, and L.J.Pike (2009).
Palmitoylation of the EGF Receptor Impairs Signal Transduction and Abolishes High-Affinity Ligand Binding (dagger).
  Biochemistry, 48, 2505-2513.  
19135477 K.J.Wilson, J.L.Gilmore, J.Foley, M.A.Lemmon, and D.J.Riese (2009).
Functional selectivity of EGF family peptide growth factors: implications for cancer.
  Pharmacol Ther, 122, 1-8.  
18992239 K.R.Schmitz, and K.M.Ferguson (2009).
Interaction of antibodies with ErbB receptor extracellular regions.
  Exp Cell Res, 315, 659-670.  
19171934 K.S.Yang, M.X.Ilagan, D.Piwnica-Worms, and L.J.Pike (2009).
Luciferase fragment complementation imaging of conformational changes in the epidermal growth factor receptor.
  J Biol Chem, 284, 7474-7482.  
19569211 K.Tanaka, M.Kawahara, H.Ueda, and T.Nagamune (2009).
Selection and growth regulation of genetically modified cells with hapten-specific antibody/receptor tyrosine kinase chimera.
  Biotechnol Prog, 25, 1138-1145.  
19038249 M.A.Lemmon (2009).
Ligand-induced ErbB receptor dimerization.
  Exp Cell Res, 315, 638-648.  
19056486 M.Murillo-Carretero, A.Torroglosa, C.Castro, A.Villalobo, and C.Estrada (2009).
S-Nitrosylation of the epidermal growth factor receptor: a regulatory mechanism of receptor tyrosine kinase activity.
  Free Radic Biol Med, 46, 471-479.  
20477507 M.Yamauchi, and N.Gotoh (2009).
Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates.
  Biomark Med, 3, 139-151.  
19563760 N.Jura, N.F.Endres, K.Engel, S.Deindl, R.Das, M.H.Lamers, D.E.Wemmer, X.Zhang, and J.Kuriyan (2009).
Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment.
  Cell, 137, 1293-1307.
PDB code: 3gt8
19804359 P.Camaj, H.Seeliger, I.Ischenko, S.Krebs, H.Blum, E.N.De Toni, D.Faktorova, K.W.Jauch, and C.J.Bruns (2009).
EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells.
  Biol Chem, 390, 1293-1302.  
  19048033 P.Jin, J.Zhang, M.Beryt, L.Turin, C.Brdlik, Y.Feng, X.Bai, J.Liu, B.Jorgensen, and H.M.Shepard (2009).
Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands.
  Mol Med, 15, 11-20.  
18761339 R.Bose, and X.Zhang (2009).
The ErbB kinase domain: structural perspectives into kinase activation and inhibition.
  Exp Cell Res, 315, 649-658.  
19258037 V.Ratushny, I.Astsaturov, B.A.Burtness, E.A.Golemis, and J.S.Silverman (2009).
Targeting EGFR resistance networks in head and neck cancer.
  Cell Signal, 21, 1255-1268.  
19040357 Y.Liu, C.T.Kuan, J.Mi, X.Zhang, B.M.Clary, D.D.Bigner, and B.A.Sullenger (2009).
Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis.
  Biol Chem, 390, 137-144.  
19480569 Y.Yang, Y.Zhao, B.Chen, Q.Han, W.Sun, Z.Xiao, and J.Dai (2009).
Collagen-binding human epidermal growth factor promotes cellularization of collagen scaffolds.
  Tissue Eng Part A, 15, 3589-3596.  
18487307 A.Szabó, G.Horváth, J.Szöllosi, and P.Nagy (2008).
Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements.
  Biophys J, 95, 2086-2096.  
18570899 A.Whitty, and T.V.Riera (2008).
New ways to target old receptors.
  Curr Opin Chem Biol, 12, 427-433.  
18652537 C.Boucher, G.St-Laurent, M.Loignon, M.Jolicoeur, G.De Crescenzo, and Y.Durocher (2008).
The bioactivity and receptor affinity of recombinant tagged EGF designed for tissue engineering applications is defined by the nature and position of the tags.
  Tissue Eng Part A, 14, 2069-2077.  
18334220 C.Qiu, M.K.Tarrant, S.H.Choi, A.Sathyamurthy, R.Bose, S.Banjade, A.Pal, W.G.Bornmann, M.A.Lemmon, P.A.Cole, and D.J.Leahy (2008).
Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
  Structure, 16, 460-467.
PDB codes: 3bbt 3bbw 3bce
18812509 C.Reissner, M.Klose, R.Fairless, and M.Missler (2008).
Mutational analysis of the neurexin/neuroligin complex reveals essential and regulatory components.
  Proc Natl Acad Sci U S A, 105, 15124-15129.  
18500331 D.E.Klein, S.E.Stayrook, F.Shi, K.Narayan, and M.A.Lemmon (2008).
Structural basis for EGFR ligand sequestration by Argos.
  Nature, 453, 1271-1275.
PDB codes: 3c9a 3ca7 3cgu
18942860 E.Park, R.Baron, and R.Landgraf (2008).
Higher-order association states of cellular ERBB3 probed with photo-cross-linkable aptamers.
  Biochemistry, 47, 11992-12005.  
18798529 G.K.Dy, and A.A.Adjei (2008).
Systemic cancer therapy: evolution over the last 60 years.
  Cancer, 113, 1857-1887.  
18199660 I.Iloro, D.Narváez, N.Guillén, C.M.Camacho, L.Guillén, E.Cora, and B.Pastrana-Ríos (2008).
The kinetics of the hydrogen/deuterium exchange of epidermal growth factor receptor ligands.
  Biophys J, 94, 4041-4055.  
18427122 J.J.Lammerts van Bueren, W.K.Bleeker, A.Brännström, A.von Euler, M.Jansson, M.Peipp, T.Schneider-Merck, T.Valerius, J.G.van de Winkel, and P.W.Parren (2008).
The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.
  Proc Natl Acad Sci U S A, 105, 6109-6114.  
18165319 J.L.Macdonald, and L.J.Pike (2008).
Heterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating system.
  Proc Natl Acad Sci U S A, 105, 112-117.  
18394559 J.Schmiedel, A.Blaukat, S.Li, T.Knöchel, and K.M.Ferguson (2008).
Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
  Cancer Cell, 13, 365-373.
PDB codes: 3c08 3c09
18773073 K.Buac, D.E.Watkins-Chow, S.K.Loftus, D.M.Larson, A.Incao, G.Gibney, and W.J.Pavan (2008).
A Sox10 expression screen identifies an amino acid essential for Erbb3 function.
  PLoS Genet, 4, e1000177.  
18573086 K.M.Ferguson (2008).
Structure-based view of epidermal growth factor receptor regulation.
  Annu Rev Biophys, 37, 353-373.  
18288481 K.Roepstorff, L.Grøvdal, M.Grandal, M.Lerdrup, and B.van Deurs (2008).
Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer.
  Histochem Cell Biol, 129, 563-578.  
18681486 L.X.Wang, and M.Agulnik (2008).
Promising newer molecular-targeted therapies in head and neck cancer.
  Drugs, 68, 1609-1619.  
18771282 L.Z.Mi, M.J.Grey, N.Nishida, T.Walz, C.Lu, and T.A.Springer (2008).
Functional and structural stability of the epidermal growth factor receptor in detergent micelles and phospholipid nanodiscs.
  Biochemistry, 47, 10314-10323.  
18347020 M.Gangloff, A.Murali, J.Xiong, C.J.Arnot, A.N.Weber, A.M.Sandercock, C.V.Robinson, R.Sarisky, A.Holzenburg, C.Kao, and N.J.Gay (2008).
Structural insight into the mechanism of activation of the Toll receptor by the dimeric ligand Spätzle.
  J Biol Chem, 283, 14629-14635.  
18259690 M.J.Wieduwilt, and M.M.Moasser (2008).
The epidermal growth factor receptor family: biology driving targeted therapeutics.
  Cell Mol Life Sci, 65, 1566-1584.  
18031935 M.Landau, and N.Ben-Tal (2008).
Dynamic equilibrium between multiple active and inactive conformations explains regulation and oncogenic mutations in ErbB receptors.
  Biochim Biophys Acta, 1785, 12-31.  
18365190 O.Samna Soumana, N.Garnier, and M.Genest (2008).
Insight into the recognition patterns of the ErbB receptor family transmembrane domains: heterodimerization models through molecular dynamics search.
  Eur Biophys J, 37, 851-864.  
18230610 P.Cironi, I.A.Swinburne, and P.A.Silver (2008).
Enhancement of cell type specificity by quantitative modulation of a chimeric ligand.
  J Biol Chem, 283, 8469-8476.  
18640841 P.De Meyts (2008).
The insulin receptor: a prototype for dimeric, allosteric membrane receptors?
  Trends Biochem Sci, 33, 376-384.  
18324780 P.R.Sheth, J.L.Hays, L.A.Elferink, and S.J.Watowich (2008).
Biochemical basis for the functional switch that regulates hepatocyte growth factor receptor tyrosine kinase activation.
  Biochemistry, 47, 4028-4038.  
18412625 R.E.van Kesteren, J.S.Gagatek, A.Hagendorf, Y.Gouwenberg, A.B.Smit, and N.I.Syed (2008).
Postsynaptic expression of an epidermal growth factor receptor regulates cholinergic synapse formation between identified molluscan neurons.
  Eur J Neurosci, 27, 2043-2056.  
17890389 S.E.Webb, S.K.Roberts, S.R.Needham, C.J.Tynan, D.J.Rolfe, M.D.Winn, D.T.Clarke, R.Barraclough, and M.L.Martin-Fernandez (2008).
Single-molecule imaging and fluorescence lifetime imaging microscopy show different structures for high- and low-affinity epidermal growth factor receptors in A431 cells.
  Biophys J, 94, 803-819.  
18275813 S.Li, P.Kussie, and K.M.Ferguson (2008).
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.
  Structure, 16, 216-227.
PDB codes: 3b2u 3b2v
18033688 T.Yoshida, I.Okamoto, T.Okabe, T.Iwasa, T.Satoh, K.Nishio, M.Fukuoka, and K.Nakagawa (2008).
Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
  Int J Cancer, 122, 1530-1538.  
18762250 X.Li, Y.Huang, J.Jiang, and S.J.Frank (2008).
ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling.
  Cell Signal, 20, 2145-2155.  
18039657 Y.X.Fan, L.Wong, J.Ding, N.A.Spiridonov, R.C.Johnson, and G.R.Johnson (2008).
Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism.
  J Biol Chem, 283, 1588-1596.  
18264138 Z.Cai, G.Zhang, Z.Zhou, K.Bembas, J.A.Drebin, M.I.Greene, and H.Zhang (2008).
Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes.
  Oncogene, 27, 3870-3874.  
17922650 A.A.Terentiev, and N.T.Moldogazieva (2007).
Cell adhesion proteins and alpha-fetoprotein. Similar structural motifs as prerequisites for common functions.
  Biochemistry (Mosc), 72, 920-935.  
17311283 A.K.Iyer, K.T.Tran, C.W.Borysenko, M.Cascio, C.J.Camacho, H.C.Blair, I.Bahar, and A.Wells (2007).
Tenascin cytotactin epidermal growth factor-like repeat binds epidermal growth factor receptor with low affinity.
  J Cell Physiol, 211, 748-758.  
17096356 A.Kolb, J.Kleeff, N.Arnold, N.A.Giese, T.Giese, M.Korc, and H.Friess (2007).
Expression and differential signaling of heregulins in pancreatic cancer cells.
  Int J Cancer, 120, 514-523.  
17875215 A.L.Stratford, G.Habibi, A.Astanehe, H.Jiang, K.Hu, E.Park, A.Shadeo, T.P.Buys, W.Lam, T.Pugh, M.Marra, T.O.Nielsen, U.Klinge, P.R.Mertens, S.Aparicio, and S.E.Dunn (2007).
Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.
  Breast Cancer Res, 9, R61.  
17555368 B.Burtness (2007).
Her signaling in pancreatic cancer.
  Expert Opin Biol Ther, 7, 823-829.  
17280834 C.W.Ward, M.C.Lawrence, V.A.Streltsov, T.E.Adams, and N.M.McKern (2007).
The insulin and EGF receptor structures: new insights into ligand-induced receptor activation.
  Trends Biochem Sci, 32, 129-137.  
18059449 D.J.Leahy (2007).
A monkey wrench in the kinase machine.
  Nat Struct Mol Biol, 14, 1120-1121.  
17314037 E.M.Bublil, and Y.Yarden (2007).
The EGF receptor family: spearheading a merger of signaling and therapeutics.
  Curr Opin Cell Biol, 19, 124-134.  
17671639 H.Zhang, A.Berezov, Q.Wang, G.Zhang, J.Drebin, R.Murali, and M.I.Greene (2007).
ErbB receptors: from oncogenes to targeted cancer therapies.
  J Clin Invest, 117, 2051-2058.  
18059446 I.Amit, R.Wides, and Y.Yarden (2007).
Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy.
  Mol Syst Biol, 3, 151.  
18075577 J.Kuriyan, and D.Eisenberg (2007).
The origin of protein interactions and allostery in colocalization.
  Nature, 450, 983-990.  
17697999 J.P.Dawson, Z.Bu, and M.A.Lemmon (2007).
Ligand-induced structural transitions in ErbB receptor extracellular domains.
  Structure, 15, 942-954.  
17245490 M.Hatakeyama (2007).
System properties of ErbB receptor signaling for the understanding of cancer progression.
  Mol Biosyst, 3, 111-116.  
17306385 M.Katz, I.Amit, and Y.Yarden (2007).
Regulation of MAPKs by growth factors and receptor tyrosine kinases.
  Biochim Biophys Acta, 1773, 1161-1176.  
17468161 P.Liu, T.Sudhaharan, R.M.Koh, L.C.Hwang, S.Ahmed, I.N.Maruyama, and T.Wohland (2007).
Investigation of the dimerization of proteins from the epidermal growth factor receptor family by single wavelength fluorescence cross-correlation spectroscopy.
  Biophys J, 93, 684-698.  
17274834 R.Landgraf (2007).
HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks.
  Breast Cancer Res, 9, 202.  
17894821 S.F.Cummins, F.Xie, M.R.de Vries, S.P.Annangudi, M.Misra, B.M.Degnan, J.V.Sweedler, G.T.Nagle, and C.H.Schein (2007).
Aplysia temptin - the 'glue' in the water-borne attractin pheromone complex.
  FEBS J, 274, 5425-5437.  
17339314 S.J.Chan, S.Nakagawa, and D.F.Steiner (2007).
Complementation analysis demonstrates that insulin cross-links both alpha subunits in a truncated insulin receptor dimer.
  J Biol Chem, 282, 13754-13758.  
17306972 S.R.Hubbard, and W.T.Miller (2007).
Receptor tyrosine kinases: mechanisms of activation and signaling.
  Curr Opin Cell Biol, 19, 117-123.  
17496034 S.Saffarian, Y.Li, E.L.Elson, and L.J.Pike (2007).
Oligomerization of the EGF receptor investigated by live cell fluorescence intensity distribution analysis.
  Biophys J, 93, 1021-1031.  
17804794 W.D.Tolbert, J.Daugherty, C.Gao, Q.Xie, C.Miranti, E.Gherardi, G.V.Woude, and H.E.Xu (2007).
A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist.
  Proc Natl Acad Sci U S A, 104, 14592-14597.
PDB codes: 2qj2 2qj4
16829981 A.Citri, and Y.Yarden (2006).
EGF-ERBB signalling: towards the systems level.
  Nat Rev Mol Cell Biol, 7, 505-516.  
16531225 A.Sivasubramanian, G.Chao, H.M.Pressler, K.D.Wittrup, and J.J.Gray (2006).
Structural model of the mAb 806-EGFR complex using computational docking followed by computational and experimental mutagenesis.
  Structure, 14, 401-414.
PDB codes: 2exp 2exq
16825199 C.M.Warren, K.Kani, and R.Landgraf (2006).
The N-terminal domains of neuregulin 1 confer signal attenuation.
  J Biol Chem, 281, 27306-27316.  
16865534 C.Sweeney, J.K.Miller, D.L.Shattuck, and K.L.Carraway (2006).
ErbB receptor negative regulatory mechanisms: implications in cancer.
  J Mammary Gland Biol Neoplasia, 11, 89-99.  
16963452 C.Zahnd, F.Pecorari, N.Straumann, E.Wyler, and A.Plückthun (2006).
Selection and characterization of Her2 binding-designed ankyrin repeat proteins.
  J Biol Chem, 281, 35167-35175.  
16537482 E.Gherardi, S.Sandin, M.V.Petoukhov, J.Finch, M.E.Youles, L.G.Ofverstedt, R.N.Miguel, T.L.Blundell, G.F.Vande Woude, U.Skoglund, and D.I.Svergun (2006).
Structural basis of hepatocyte growth factor/scatter factor and MET signalling.
  Proc Natl Acad Sci U S A, 103, 4046-4051.
PDB codes: 2ced 2cee 2ceg 2cew
16533841 H.Shankaran, H.S.Wiley, and H.Resat (2006).
Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response.
  Biophys J, 90, 3993-4009.  
16433931 H.T.Chang, T.W.Pai, T.C.Fan, B.H.Su, P.C.Wu, C.Y.Tang, C.T.Chang, S.H.Liu, and M.D.Chang (2006).
A reinforced merging methodology for mapping unique peptide motifs in members of protein families.
  BMC Bioinformatics, 7, 38.  
16499962 J.Ichinose, M.Morimatsu, T.Yanagida, and Y.Sako (2006).
Covalent immobilization of epidermal growth factor molecules for single-molecule imaging analysis of intracellular signaling.
  Biomaterials, 27, 3343-3350.  
16546374 J.J.Gray (2006).
High-resolution protein-protein docking.
  Curr Opin Struct Biol, 16, 183-193.  
16842869 J.Macdonald, Z.Li, W.Su, and L.J.Pike (2006).
The membrane proximal disulfides of the EGF receptor extracellular domain are required for high affinity binding and signal transduction but do not play a role in the localization of the receptor to lipid rafts.
  Biochim Biophys Acta, 1763, 870-878.  
16267617 J.N.Contessa, A.Abell, R.B.Mikkelsen, K.Valerie, and R.K.Schmidt-Ullrich (2006).
Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
  Breast Cancer Res Treat, 95, 17-27.  
16411922 M.Date, H.Itaya, H.Matsui, and Y.Kikuchi (2006).
Secretion of human epidermal growth factor by Corynebacterium glutamicum.
  Lett Appl Microbiol, 42, 66-70.  
18360654 N.Starling, J.Neoptolemos, and D.Cunningham (2006).
Role of erlotinib in the management of pancreatic cancer.
  Ther Clin Risk Manag, 2, 435-445.  
16597832 N.Y.Lee, T.L.Hazlett, and J.G.Koland (2006).
Structure and dynamics of the epidermal growth factor receptor C-terminal phosphorylation domain.
  Protein Sci, 15, 1142-1152.  
16928683 P.P.Knowles, J.Murray-Rust, S.Kjaer, R.P.Scott, S.Hanrahan, M.Santoro, C.F.Ibáñez, and N.Q.McDonald (2006).
Structure and chemical inhibition of the RET tyrosine kinase domain.
  J Biol Chem, 281, 33577-33587.
PDB codes: 2ivs 2ivt 2ivu 2ivv
17026767 R.A.Stein, and J.V.Staros (2006).
Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis.
  BMC Evol Biol, 6, 79.  
16380971 S.Aifa, N.Miled, F.Frikha, M.R.Aniba, S.P.Svensson, and A.Rebai (2006).
Electrostatic interactions of peptides flanking the tyrosine kinase domain in the epidermal growth factor receptor provides a model for intracellular dimerization and autophosphorylation.
  Proteins, 62, 1036-1043.  
16788977 S.Kamath, and J.K.Buolamwini (2006).
Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development.
  Med Res Rev, 26, 569-594.  
18377216 S.Meierjohann, T.Mueller, M.Schartl, and M.Buehner (2006).
A structural model of the extracellular domain of the oncogenic EGFR variant Xmrk.
  Zebrafish, 3, 359-369.  
17032651 S.P.van der Woning, W.van Rotterdam, S.B.Nabuurs, H.Venselaar, S.Jacobs-Oomen, M.Wingens, G.Vriend, C.Stortelers, and E.J.van Zoelen (2006).
Negative constraints underlie the ErbB specificity of epidermal growth factor-like ligands.
  J Biol Chem, 281, 40033-40040.  
16889899 S.Sebastian, J.Settleman, S.J.Reshkin, A.Azzariti, A.Bellizzi, and A.Paradiso (2006).
The complexity of targeting EGFR signalling in cancer: from expression to turnover.
  Biochim Biophys Acta, 1766, 120-139.  
16624867 V.P.Ramsauer, V.Pino, A.Farooq, C.A.Carothers Carraway, P.J.Salas, and K.L.Carraway (2006).
Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2.
  Mol Biol Cell, 17, 2931-2941.  
16732286 W.A.Barton, D.Tzvetkova-Robev, E.P.Miranda, M.V.Kolev, K.R.Rajashankar, J.P.Himanen, and D.B.Nikolov (2006).
Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2-Tie2 complex.
  Nat Struct Mol Biol, 13, 524-532.
PDB codes: 2gy5 2gy7
16777603 X.Zhang, J.Gureasko, K.Shen, P.A.Cole, and J.Kuriyan (2006).
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.
  Cell, 125, 1137-1149.
PDB codes: 2gs2 2gs6 2gs7
16355407 Y.S.Kim, R.Bhandari, J.R.Cochran, J.Kuriyan, and K.D.Wittrup (2006).
Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast.
  Proteins, 62, 1026-1035.  
16946702 Y.Teramura, J.Ichinose, H.Takagi, K.Nishida, T.Yanagida, and Y.Sako (2006).
Single-molecule analysis of epidermal growth factor binding on the surface of living cells.
  EMBO J, 25, 4215-4222.  
15994331 A.H.Clayton, F.Walker, S.G.Orchard, C.Henderson, D.Fuchs, J.Rothacker, E.C.Nice, and A.W.Burgess (2005).
Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis.
  J Biol Chem, 280, 30392-30399.  
15795223 A.N.Weber, M.C.Moncrieffe, M.Gangloff, J.L.Imler, and N.J.Gay (2005).
Ligand-receptor and receptor-receptor interactions act in concert to activate signaling in the Drosophila toll pathway.
  J Biol Chem, 280, 22793-22799.  
15880563 A.P.Venook (2005).
Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma.
  Cancer, 103, 2435-2446.  
16050785 B.Burtness (2005).
The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
  Expert Opin Biol Ther, 5, 1085-1093.  
15611079 B.S.Kochupurakkal, D.Harari, A.Di-Segni, G.Maik-Rachline, L.Lyass, G.Gur, G.Kerber, A.Citri, S.Lavi, R.Eilam, V.Chalifa-Caspi, Z.Eshhar, E.Pikarsky, R.Pinkas-Kramarski, S.S.Bacus, and Y.Yarden (2005).
Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity.
  J Biol Chem, 280, 8503-8512.  
16207817 C.Haslekås, K.Breen, K.W.Pedersen, L.E.Johannessen, E.Stang, and I.H.Madshus (2005).
The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane.
  Mol Biol Cell, 16, 5832-5842.  
15822127 C.Luo, L.Xu, S.Zheng, X.Luo, J.Shen, H.Jiang, X.Liu, and M.Zhou (2005).
Computational analysis of molecular basis of 1:1 interactions of NRG-1beta wild-type and variants with ErbB3 and ErbB4.
  Proteins, 59, 742-756.  
15688065 C.P.Blobel (2005).
ADAMs: key components in EGFR signalling and development.
  Nat Rev Mol Cell Biol, 6, 32-43.  
16103229 D.S.Lidke, K.A.Lidke, B.Rieger, T.M.Jovin, and D.J.Arndt-Jovin (2005).
Reaching out for signals: filopodia sense EGF and respond by directed retrograde transport of activated receptors.
  J Cell Biol, 170, 619-626.  
16265350 G.N.Berta, B.Mognetti, M.Spadaro, E.Trione, A.Amici, G.Forni, F.Di Carlo, and F.Cavallo (2005).
Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas.
  Br J Cancer, 93, 1250-1256.  
16212492 G.Vert, J.L.Nemhauser, N.Geldner, F.Hong, and J.Chory (2005).
Molecular mechanisms of steroid hormone signaling in plants.
  Annu Rev Cell Dev Biol, 21, 177-201.  
16185155 J.G.Shelton, L.S.Steelman, S.L.Abrams, F.E.Bertrand, R.A.Franklin, M.McMahon, and J.A.McCubrey (2005).
The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?
  Expert Opin Ther Targets, 9, 1009-1030.  
16107719 J.P.Dawson, M.B.Berger, C.C.Lin, J.Schlessinger, M.A.Lemmon, and K.M.Ferguson (2005).
Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface.
  Mol Cell Biol, 25, 7734-7742.  
15840573 K.Choowongkomon, C.R.Carlin, and F.D.Sönnichsen (2005).
A structural model for the membrane-bound form of the juxtamembrane domain of the epidermal growth factor receptor.
  J Biol Chem, 280, 24043-24052.
PDB code: 1z9i
15611073 K.Kani, C.M.Warren, C.S.Kaddis, J.A.Loo, and R.Landgraf (2005).
Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin.
  J Biol Chem, 280, 8238-8247.  
15480783 M.J.Oliveira, T.Lauwaet, G.De Bruyne, M.Mareel, and A.Leroy (2005).
Listeria monocytogenes produces a pro-invasive factor that signals via ErbB2/ErbB3 heterodimers.
  J Cancer Res Clin Oncol, 131, 49-59.  
15864276 N.E.Hynes, and H.A.Lane (2005).
ERBB receptors and cancer: the complexity of targeted inhibitors.
  Nat Rev Cancer, 5, 341-354.  
15660449 P.Aller, L.Voiry, N.Garnier, and M.Genest (2005).
Molecular dynamics (MD) investigations of preformed structures of the transmembrane domain of the oncogenic Neu receptor dimer in a DMPC bilayer.
  Biopolymers, 77, 184-197.  
15596490 P.Bagossi, G.Horváth, G.Vereb, J.Szöllösi, and J.Tözsér (2005).
Molecular modeling of nearly full-length ErbB2 receptor.
  Biophys J, 88, 1354-1363.  
15920761 P.Hu, J.Feng, T.Zhou, J.Wang, B.Jing, M.Yu, M.Hu, X.Zhang, B.Shen, and N.Guo (2005).
In vivo identification of the interaction site of ErbB2 extracellular domain with its autoinhibitor.
  J Cell Physiol, 205, 335-343.  
16203964 S.Bouyain, P.A.Longo, S.Li, K.M.Ferguson, and D.J.Leahy (2005).
The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
  Proc Natl Acad Sci U S A, 102, 15024-15029.
PDB code: 2ahx
15837620 S.Li, K.R.Schmitz, P.D.Jeffrey, J.J.Wiltzius, P.Kussie, and K.M.Ferguson (2005).
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.
  Cancer Cell, 7, 301-311.
PDB codes: 1yy8 1yy9
  15955874 S.McLaughlin, S.O.Smith, M.J.Hayman, and D.Murray (2005).
An electrostatic engine model for autoinhibition and activation of the epidermal growth factor receptor (EGFR/ErbB) family.
  J Gen Physiol, 126, 41-53.  
16338790 S.S.Hobbs, R.M.Gallo, and D.J.Riese (2005).
Phe45 of NRG2beta is critical for the affinity of NRG2beta for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2beta*.
  Growth Factors, 23, 273-283.  
15749770 T.Uyemura, H.Takagi, T.Yanagida, and Y.Sako (2005).
Single-molecule analysis of epidermal growth factor signaling that leads to ultrasensitive calcium response.
  Biophys J, 88, 3720-3730.  
16211506 X.Zuo, S.Li, J.Hall, M.R.Mattern, H.Tran, J.Shoo, R.Tan, S.R.Weiss, and T.R.Butt (2005).
Enhanced expression and purification of membrane proteins by SUMO fusion in Escherichia coli.
  J Struct Funct Genomics, 6, 103-111.  
15094157 A.Bennasroune, A.Gardin, D.Aunis, G.Crémel, and P.Hubert (2004).
Tyrosine kinase receptors as attractive targets of cancer therapy.
  Crit Rev Oncol Hematol, 50, 23-38.  
15122207 A.Gschwind, O.M.Fischer, and A.Ullrich (2004).
The discovery of receptor tyrosine kinases: targets for cancer therapy.
  Nat Rev Cancer, 4, 361-370.  
15166146 D.Alvarado, A.H.Rice, and J.B.Duffy (2004).
Bipartite inhibition of Drosophila epidermal growth factor receptor by the extracellular and transmembrane domains of Kekkon1.
  Genetics, 167, 187-202.  
14732693 D.Mattoon, P.Klein, M.A.Lemmon, I.Lax, and J.Schlessinger (2004).
The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function.
  Proc Natl Acad Sci U S A, 101, 923-928.  
15016810 F.Walker, S.G.Orchard, R.N.Jorissen, N.E.Hall, H.H.Zhang, P.A.Hoyne, T.E.Adams, T.G.Johns, C.Ward, T.P.Garrett, H.J.Zhu, M.Nerrie, A.M.Scott, E.C.Nice, and A.W.Burgess (2004).
CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor.
  J Biol Chem, 279, 22387-22398.  
14748658 G.M.Higa (2004).
Targeted therapies in oncology: in the crosshairs or at the crossroads?
  Expert Rev Anticancer Ther, 4, 61-75.  
15606339 G.M.Higa (2004).
Signaling multiplex of the epidermal growth factor receptor.
  Expert Rev Anticancer Ther, 4, 1145-1156.  
15235591 J.Kniazeff, A.S.Bessis, D.Maurel, H.Ansanay, L.Prézeau, and J.P.Pin (2004).
Closed state of both binding domains of homodimeric mGlu receptors is required for full activity.
  Nat Struct Mol Biol, 11, 706-713.  
15049825 M.Banerjee, J.Copp, D.Vuga, M.Marino, T.Chapman, P.van der Geer, and P.Ghosh (2004).
GW domains of the Listeria monocytogenes invasion protein InlB are required for potentiation of Met activation.
  Mol Microbiol, 52, 257-271.  
15093539 M.C.Franklin, K.D.Carey, F.F.Vajdos, D.J.Leahy, A.M.de Vos, and M.X.Sliwkowski (2004).
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.
  Cancer Cell, 5, 317-328.
PDB code: 1s78
15070899 M.Kim, H.Yang, S.K.Kim, P.A.Reche, R.S.Tirabassi, R.E.Hussey, Y.Chishti, J.G.Rheinwald, T.J.Morehead, T.Zech, I.K.Damon, R.M.Welsh, and E.L.Reinherz (2004).
Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies.
  J Biol Chem, 279, 25838-25848.  
15576039 M.Landau, S.J.Fleishman, and N.Ben-Tal (2004).
A putative mechanism for downregulation of the catalytic activity of the EGF receptor via direct contact between its kinase and C-terminal domains.
  Structure, 12, 2265-2275.  
15215236 M.Offterdinger, V.Georget, A.Girod, and P.I.Bastiaens (2004).
Imaging phosphorylation dynamics of the epidermal growth factor receptor.
  J Biol Chem, 279, 36972-36981.  
14993704 N.Kulahin, C.Kasper, M.Gajhede, V.Berezin, E.Bock, and J.S.Kastrup (2004).
Expression, crystallization and preliminary X-ray analysis of extracellular modules of the neural cell-adhesion molecules NCAM and L1.
  Acta Crystallogr D Biol Crystallogr, 60, 591-593.  
14732694 P.Klein, D.Mattoon, M.A.Lemmon, and J.Schlessinger (2004).
A structure-based model for ligand binding and dimerization of EGF receptors.
  Proc Natl Acad Sci U S A, 101, 929-934.  
15331606 R.Takazaki, Y.Shishido, R.Iwamoto, and E.Mekada (2004).
Suppression of the biological activities of the epidermal growth factor (EGF)-like domain by the heparin-binding domain of heparin-binding EGF-like Growth Factor.
  J Biol Chem, 279, 47335-47343.  
15238521 T.Donaldson, S.H.Wang, T.L.Jacobsen, B.Schnepp, J.Price, and A.Simcox (2004).
Regulation of the Drosophila epidermal growth factor-ligand vein is mediated by multiple domains.
  Genetics, 167, 687-698.  
15075331 T.G.Johns, T.E.Adams, J.R.Cochran, N.E.Hall, P.A.Hoyne, M.J.Olsen, Y.S.Kim, J.Rothacker, E.C.Nice, F.Walker, G.Ritter, A.A.Jungbluth, L.J.Old, C.W.Ward, A.W.Burgess, K.D.Wittrup, and A.M.Scott (2004).
Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
  J Biol Chem, 279, 30375-30384.  
14744244 T.Holbro, and N.E.Hynes (2004).
ErbB receptors: directing key signaling networks throughout life.
  Annu Rev Pharmacol Toxicol, 44, 195-217.  
15231819 Y.X.Fan, L.Wong, T.B.Deb, and G.R.Johnson (2004).
Ligand regulates epidermal growth factor receptor kinase specificity: activation increases preference for GAB1 and SHC versus autophosphorylation sites.
  J Biol Chem, 279, 38143-38150.  
14527402 A.W.Burgess, H.S.Cho, C.Eigenbrot, K.M.Ferguson, T.P.Garrett, D.J.Leahy, M.A.Lemmon, M.X.Sliwkowski, C.W.Ward, and S.Yokoyama (2003).
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.
  Mol Cell, 12, 541-552.  
12614348 B.Malissen (2003).
An evolutionary and structural perspective on T cell antigen receptor function.
  Immunol Rev, 191, 7.  
12734179 C.Couturier, and R.Jockers (2003).
Activation of the leptin receptor by a ligand-induced conformational change of constitutive receptor dimers.
  J Biol Chem, 278, 26604-26611.  
12874383 C.H.Chen, G.A.Chernis, V.Q.Hoang, and R.Landgraf (2003).
Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.
  Proc Natl Acad Sci U S A, 100, 9226-9231.  
12556529 C.Stortelers, S.P.van der Woning, S.Jacobs-Oomen, M.Wingens, and E.J.van Zoelen (2003).
Selective formation of ErbB-2/ErbB-3 heterodimers depends on the ErbB-3 affinity of epidermal growth factor-like ligands.
  J Biol Chem, 278, 12055-12063.  
14632199 C.Stove, V.Stove, L.Derycke, V.Van Marck, M.Mareel, and M.Bracke (2003).
The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation.
  J Invest Dermatol, 121, 802-812.  
14528000 E.Gherardi, M.E.Youles, R.N.Miguel, T.L.Blundell, L.Iamele, J.Gough, A.Bandyopadhyay, G.Hartmann, and P.J.Butler (2003).
Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor.
  Proc Natl Acad Sci U S A, 100, 12039-12044.  
14530278 E.J.Westover, D.F.Covey, H.L.Brockman, R.E.Brown, and L.J.Pike (2003).
Cholesterol depletion results in site-specific increases in epidermal growth factor receptor phosphorylation due to membrane level effects. Studies with cholesterol enantiomers.
  J Biol Chem, 278, 51125-51133.  
12707299 F.Lühder, Y.Huang, K.M.Dennehy, C.Guntermann, I.Müller, E.Winkler, T.Kerkau, S.Ikemizu, S.J.Davis, T.Hanke, and T.Hünig (2003).
Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists.
  J Exp Med, 197, 955-966.  
12610629 H.S.Cho, K.Mason, K.X.Ramyar, A.M.Stanley, S.B.Gabelli, D.W.Denney, and D.J.Leahy (2003).
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.
  Nature, 421, 756-760.
PDB codes: 1n8y 1n8z
  12813928 H.S.Earp, B.F.Calvo, and C.I.Sartor (2003).
The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4.
  Trans Am Clin Climatol Assoc, 114, 315.  
12667445 J.Greenwald, J.Groppe, P.Gray, E.Wiater, W.Kwiatkowski, W.Vale, and S.Choe (2003).
The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly.
  Mol Cell, 11, 605-617.
PDB codes: 1lx5 1lxi
12620237 K.M.Ferguson, M.B.Berger, J.M.Mendrola, H.S.Cho, D.J.Leahy, and M.A.Lemmon (2003).
EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.
  Mol Cell, 11, 507-517.
PDB code: 1nql
12791136 M.P.Machner, S.Frese, W.D.Schubert, V.Orian-Rousseau, E.Gherardi, J.Wehland, H.H.Niemann, and D.W.Heinz (2003).
Aromatic amino acids at the surface of InlB are essential for host cell invasion by Listeria monocytogenes.
  Mol Microbiol, 48, 1525-1536.  
12869572 M.Wingens, T.Walma, H.van Ingen, C.Stortelers, J.E.van Leeuwen, E.J.van Zoelen, and G.W.Vuister (2003).
Structural analysis of an epidermal growth factor/transforming growth factor-alpha chimera with unique ErbB binding specificity.
  J Biol Chem, 278, 39114-39123.
PDB code: 1p9j
12605220 M.X.Sliwkowski (2003).
Ready to partner.
  Nat Struct Biol, 10, 158-159.  
12695504 S.Schenk, E.Hintermann, M.Bilban, N.Koshikawa, C.Hojilla, R.Khokha, and V.Quaranta (2003).
Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution.
  J Cell Biol, 161, 197-209.  
12620236 T.P.Garrett, N.M.McKern, M.Lou, T.C.Elleman, T.E.Adams, G.O.Lovrecz, M.Kofler, R.N.Jorissen, E.C.Nice, A.W.Burgess, and C.W.Ward (2003).
The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors.
  Mol Cell, 11, 495-505.
PDB code: 2a91
14708119 W.S.Hlavacek, J.R.Faeder, M.L.Blinov, A.S.Perelson, and B.Goldstein (2003).
The complexity of complexes in signal transduction.
  Biotechnol Bioeng, 84, 783-794.  
12731890 Y.Zhen, R.M.Caprioli, and J.V.Staros (2003).
Characterization of glycosylation sites of the epidermal growth factor receptor.
  Biochemistry, 42, 5478-5492.  
12196540 J.Stamos, M.X.Sliwkowski, and C.Eigenbrot (2002).
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor.
  J Biol Chem, 277, 46265-46272.
PDB codes: 1m14 1m17
12297049 T.P.Garrett, N.M.McKern, M.Lou, T.C.Elleman, T.E.Adams, G.O.Lovrecz, H.J.Zhu, F.Walker, M.J.Frenkel, P.A.Hoyne, R.N.Jorissen, E.C.Nice, A.W.Burgess, and C.W.Ward (2002).
Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha.
  Cell, 110, 763-773.
PDB code: 1mox
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB codes are shown on the right.